PMID- 11829731
OWN - NLM
STAT- MEDLINE
DCOM- 20020724
LR  - 20190916
IS  - 1465-6566 (Print)
IS  - 1465-6566 (Linking)
VI  - 3
IP  - 2
DP  - 2002 Feb
TI  - Reviparin sodium - a new low molecular weight heparin.
PG  - 173-82
AB  - Reviparin sodium (Clivarine), Knoll AG) is a low molecular weight heparin (LMWH) 
      with a mean peak molecular weight of 3900 Da. It is characterised by a narrow 
      molecular weight distribution profile, with an anti-factor Xa 
      (anti-Xa):anti-factor IIa (anti-IIa) ratio of >or=3.6. In healthy human 
      volunteers, plasma anti-Xa activity was up to five times higher and lasted three 
      times longer with reviparin compared with unfractionated heparin (UFH). Unlike 
      UFH, reviparin has negligible effects on global clotting tests. Reviparin has 
      been shown to be as effective as UFH in different prophylactic indications and 
      causes fewer injection-site haematomas. At a daily dose of 1750 IU anti-Xa it was 
      as effective as UFH in preventing deep vein thrombosis (DVT) in moderate risk 
      surgery (general and abdominal) and significantly reduced DVT in patients with 
      brace immobilisation of the legs. At a daily dose of 4200 IU anti-Xa reviparin 
      was as effective as UFH or enoxaparin in preventing DVT in high risk orthopaedic 
      surgery and as effective as UFH in prevention of DVT and/or pulmonary embolism 
      (PE) and/or mortality in high risk orthopaedic surgery. In patients with acute 
      venous thromboembolism (VTE), reviparin was more effective than UFH in thrombus 
      reduction and at least as effective as UFH in the prevention of clinical 
      recurrence of DVT and/or PE. The use of reviparin is associated with a similar or 
      lower incidence of bleeding complications than UFH.
FAU - Breddin, Hans Klaus
AU  - Breddin HK
AD  - International Institute of Thrombosis and Vascular Diseases e.V., 
      Ferdinand-Schrey-Weg 6, D-60598 Frankfurt am Main, Germany. 
      breddin@em.uni-frankfurt.de
LA  - eng
PT  - Journal Article
PT  - Review
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Anticoagulants)
RN  - 0 (Factor Xa Inhibitors)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 5R0L1D739E (reviparin)
SB  - IM
MH  - Absorption
MH  - Anticoagulants/adverse effects/pharmacokinetics/*therapeutic use
MH  - Child
MH  - Drug Evaluation
MH  - Factor Xa Inhibitors
MH  - Female
MH  - Heparin, Low-Molecular-Weight/adverse effects/pharmacokinetics/*therapeutic use
MH  - Humans
MH  - Pregnancy
MH  - Pregnancy Complications, Hematologic/drug therapy
MH  - Thrombocytopenia/chemically induced
MH  - Thrombophilia/*drug therapy
MH  - Venous Thrombosis/*drug therapy/prevention & control
RF  - 50
EDAT- 2002/02/07 10:00
MHDA- 2002/07/26 10:01
CRDT- 2002/02/07 10:00
PHST- 2002/02/07 10:00 [pubmed]
PHST- 2002/07/26 10:01 [medline]
PHST- 2002/02/07 10:00 [entrez]
AID - 10.1517/14656566.3.2.173 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2002 Feb;3(2):173-82. doi: 10.1517/14656566.3.2.173.